Minimal Residual Disease Testing Market Insights: Flow Cytometry,...

Reflexión añadida Otro

2026-03-11 09:24:48 -

Minimal Residual Disease Testing Market Insights: Flow Cytometry, PCR, and NGS-Based MRD Platforms (2026–2034)

The minimal residual disease (MRD) testing market is a rapidly advancing segment of hematology and oncology diagnostics—enabling detection of very low levels of cancer cells that remain after treatment and that may not be visible through conventional imaging or standard laboratory measures. MRD testing is most established in blood cancers such as acute lymphoblastic leukemia, acute...

0 Commentarios 0 Compartido 55 Vistas